Hui Z, Men Y, Hu C, et al. - This randomized clinical trial (PORT-C) was conducted to assess the impact of postoperative radiotherapy (PORT) employing modern techniques on survival as well as safety in patients with pIIIA-N2 non–small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy. Participants included patients with pIIIA-N2 NSCLC managed with complete resection and 4 cycles of platinum-based chemotherapy between January 2009 and December 2017. Patients were randomly assigned equally into the PORT arm (n = 202) or the observation arm (n = 192). The total dose of PORT was 50 Gy. The 3-year overall survival rates with PORT vs with observation were 78.3% vs 82.8% and the estimated locoregional recurrence–free survival was 66.5% vs 59.7%, respectively. Findings of this phase 3 randomized clinical trial revealed that disease-free survival was not improved by PORT in patients with pIIIA-N2 NSCLC after complete resection and adjuvant chemotherapy.